GleamWall
中文EN

DERM Journey Medical Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1867066 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.0%
TTM net income YoY41.1%
TTM EPS YoY48.6%
Revenue 3-yr CAGR-4.5%
Net income 3-yr CAGR—

Margins

Gross margin65.9%
Operating margin-2.9%
Net margin-7.3%
FCF margin—
EBITDA margin—

Returns

ROE-17.6%
ROA-5.4%
ROIC (approx.)-5.2%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets68.9%
Debt / equity0.79x
Current ratio1.48x
Interest coverage-0.55x

Cash quality & payout

Operating cash flow / net income1.67x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.97M$18.51M$15.96M$16.08M$17.63M$15.01M$13.14M$13.62M
Cost of revenue$5.88M$6.14M$6.22M$5.44M$5.75M$4.94M$4.79M$2.24M
Gross profit$13.08M$12.37M$9.74M$10.64M$11.88M$10.07M$8.35M$11.38M
R&D expense$51,000$54,000—$154,000$287,000$0$39,000$218,000
SG&A expense$12.59M$10.89M$10.11M$9.86M$12.05M$11.88M$10.57M$10.06M
Operating income-$530,000$456,000-$1.49M-$443,000-$1.53M-$2.88M-$3.32M$2.23M
Interest expense$919,000$906,000$892,000$933,000$937,000$937,000$891,000$831,000
Pretax income-$1.31M-$297,000-$2.23M-$1.25M-$2.31M-$3.74M-$4.07M$1.58M
Income tax$0$15,000—$0$0$60,000——
Net income-$1.31M-$312,000-$2.23M-$1.25M-$2.31M-$3.80M-$4.07M$1.52M
EPS (basic)-0.05-0.01-0.08—-0.09-0.16-0.18—
EPS (diluted)-0.05-0.01-0.08—-0.09-0.16-0.18—
Weighted avg. shares (diluted)28.07M27.49M27.31M—24.96M23.29M22.61M—
Balance sheet
Cash & equivalents$22.32M$25.64M$27.22M$24.09M$24.95M$20.29M$21.07M$20.30M
Receivables$47.39M$36.25M$24.99M$29.78M$17.98M$15.64M$18.02M$10.23M
Inventory$7.77M$8.16M$9.29M$9.62M$11.82M$12.85M$12.50M$14.43M
Current assets$79.26M$72.78M$64.97M$66.87M$56.39M$51.27M$53.99M$48.18M
Intangibles$24.54M$25.51M$26.48M$27.61M$28.67M$29.73M$30.80M$31.86M
Total assets$103.85M$98.36M$91.53M$94.59M$85.19M$81.16M$84.96M$80.24M
Current liabilities$53.52M$45.77M$37.83M$37.44M$39.72M$40.48M$40.22M$35.17M
Short-term debt$7.50M$5.00M$2.50M—$5.62M$3.75M$1.88M—
Long-term debt$18.08M$20.47M$22.87M$25.28M$19.53M$21.36M$23.11M$24.88M
Total debt$25.58M$25.47M$25.37M$25.28M$25.16M$25.11M$24.98M$24.88M
Total liabilities$71.60M$66.24M$60.70M$62.74M$59.29M$61.91M$63.42M$60.17M
Shareholders' equity$32.25M$32.11M$30.83M$31.85M$25.90M$19.25M$21.54M$20.07M
Net debt$3.25M-$171,000-$1.85M$1.19M$211,000$4.82M$3.91M$4.57M
Cash flow statement
Operating cash flow-$3.44M-$1.73M$2.91M-$6.28M-$2.38M-$942,000-$2.83M$2.23M
Financing cash flow$117,000$158,000$220,000$5.43M$7.04M$165,000$3.60M$10.62M
Stock-based compensation$1.33M$1.44M$989,000$1.77M$1.85M$1.34M$1.32M$1.38M

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.